Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lynn O’Donnell
Observed name:
Lynn Odonnell
Institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University
Observed institutions:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University
ORCID:
0009-0006-9791-3659
Observed ORCID:
0009-0006-9791-3659
OpenAlex ID:
A5140608294
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
·
Blood Cancer Discovery
·
1
PDF
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026
·
Sumithira Vasu
, Nathan Denlinger
, et al.
Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma
2026
·
Jia-Jye Lee
, Peirong Hu
, et al.
·
iScience
Show more works
View as search
Works count:
13
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type